Mirati Therapeutics Inc Quick Ratio (MRTX) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Mirati Therapeutics Inc   (NASDAQ: MRTX)

Mirati Therapeutics Inc 's Quick Ratio

MRTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Mirati Therapeutics Inc 's Cash & cash equivalent grew by 25.27 % in the Q3 2023 sequentially, while Current Liabilities decreased, this led to improvement in Mirati Therapeutics Inc 's Quick Ratio to 7.11, Quick Ratio remained below Mirati Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 162 other companies have achieved higher Quick Ratio than Mirati Therapeutics Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the Q3 2023 to 490, from total ranking in the second quarter 2023 at 609.

Explain Quick Ratio?
How much Cash & cash equivalents MRTX´s has?
What are MRTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MRTX Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change 8.18 % 17.49 % 0.83 % 10.99 % 4.02 %
Y / Y Cash & cash equivalent Change -18.7 % -34.02 % -31.98 % -27.32 % 4.03 %
Quick Ratio MRQ 7.11 5.57 7.24 6.8 9.46
MRTX's Total Ranking # 490 # 609 # 515 # 149 # 447
Seq. Current Liabilities Change -1.87 % 12.35 % -21.86 % 25.56 % 6.58 %
Seq. Cash & cash equivalent Change 25.27 % -13.62 % -16.75 % -9.75 % 1.66 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 163
Healthcare Sector # 262
Overall Market # 490


Quick Ratio Statistics
High Average Low
19.45 8.8 0.37
(Dec 31 2020)   (Dec 31 2013)




Financial Statements
Mirati Therapeutics Inc 's Current Liabilities $ 137 Millions Visit MRTX's Balance sheet
Mirati Therapeutics Inc 's Cash & cash equivalent $ 976 Millions Visit MRTX's Balance sheet
Source of MRTX's Sales Visit MRTX's Sales by Geography


Cumulative Mirati Therapeutics Inc 's Quick Ratio

MRTX's Quick Ratio for the trailling 12 Months

MRTX Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 9.36 % 8.37 % -7.01 % 1.04 % 13.7 %
Y / Y Cash & cash equivalent TTM Growth -28.04 % -23.03 % -15.48 % -6.57 % 3.42 %
Quick Ratio TTM 6.67 7.2 8.24 9.06 10.13
Total Ranking TTM # 3461 # 3303 # 3362 # 480 # 3262
Seq. Current Liabilities TTM Growth 1.89 % 3.93 % 0.19 % 3.08 % 0.97 %
Seq. Cash & cash equivalent TTM Growth -5.66 % -9.2 % -8.85 % -7.84 % 0.9 %

Quick ratio ranking by company, industry and sector >> Back to MRTX Financial Strength Comparisons >> Go to Compare MRTX Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2023 to $137.38 millions, cumulative Quick Ratio decreased to 6.67 below the Mirati Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 515 other companies have achieved higher Quick Ratio than Mirati Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3303 to 3461.

Explain Quick Ratio?
How much Cash & cash equivalents MRTX´s has?
What are MRTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 516
Healthcare Sector # 1020
Within the Market # 3461


trailing twelve months Quick Ratio Statistics
High Average Low
14.26 10.55 6.67
(Mar 31 2021)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Akero Therapeutics Inc   19.50 $ 554.732  Millions$ 28.447  Millions
Pliant Therapeutics Inc   19.11 $ 523.612  Millions$ 27.395  Millions
Eqrx Inc   19.03 $ 1,212.933  Millions$ 63.726  Millions
Pmv Pharmaceuticals Inc   18.84 $ 201.918  Millions$ 10.716  Millions
Ideaya Biosciences Inc   18.83 $ 468.751  Millions$ 24.893  Millions
Savara Inc   18.77 $ 168.251  Millions$ 8.963  Millions
Medicinova Inc   18.38 $ 51.507  Millions$ 2.802  Millions
Immuneering Corporation  18.28 $ 97.243  Millions$ 5.321  Millions
Fulcrum Therapeutics Inc   18.27 $ 257.091  Millions$ 14.075  Millions
Stoke Therapeutics Inc   18.18 $ 214.718  Millions$ 11.811  Millions
Edgewise Therapeutics inc   17.73 $ 289.697  Millions$ 16.338  Millions
Kura Oncology Inc   17.51 $ 452.593  Millions$ 25.843  Millions
Olema Pharmaceuticals Inc   17.34 $ 276.901  Millions$ 15.966  Millions
Keros Therapeutics Inc   17.24 $ 287.893  Millions$ 16.701  Millions
Trevi Therapeutics Inc   17.18 $ 88.868  Millions$ 5.173  Millions
Cadrenal Therapeutics Inc  16.91 $ 9.109  Millions$ 0.539  Millions
Day One Biopharmaceuticals Inc   16.57 $ 405.538  Millions$ 24.475  Millions
Lyell Immunopharma Inc   16.41 $ 575.431  Millions$ 35.064  Millions
Inozyme Pharma Inc   15.68 $ 192.442  Millions$ 12.275  Millions
Barinthus Biotherapeutics Plc  15.60 $ 160.309  Millions$ 10.277  Millions
Acrivon Therapeutics Inc   15.28 $ 142.090  Millions$ 9.299  Millions
Cocrystal Pharma Inc   15.06 $ 29.813  Millions$ 1.979  Millions
Agios Pharmaceuticals Inc   14.80 $ 647.488  Millions$ 43.761  Millions
Larimar Therapeutics Inc   14.58 $ 95.590  Millions$ 6.558  Millions
Dianthus Therapeutics Inc   14.52 $ 189.870  Millions$ 13.079  Millions
Rafael Holdings Inc  14.49 $ 13.197  Millions$ 0.911  Millions
Nuvalent Inc   14.20 $ 413.258  Millions$ 29.103  Millions
Prelude Therapeutics Inc  14.04 $ 230.506  Millions$ 16.418  Millions
Verve Therapeutics Inc   14.03 $ 485.226  Millions$ 34.575  Millions
Minerva Neurosciences Inc   14.00 $ 46.904  Millions$ 3.350  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.